OS (months) | 95% CI | P value | |
---|---|---|---|
Age | |||
   < median | 15.2 | 11.5 - 19.0 | 0.491 |
   ≧ median | 12.8 | 7.1 - 18.4 | |
Gender | |||
   male | 13.2 | 9.8 - 14.8 | 0.49 |
   Female | 16.8 | 10.7 - 22.8 | |
Performance status | |||
   0-1 | 15.2 | 12.0 18.5 | 0.01 |
   ≧ 2 | 7.6 | 0 - 16.5 | |
Disease status | |||
   Advanced | 15.2 | 11.7 - 18.8 | 0.24 |
   Recurrent | 12.1 | 9.1 - 15.1 | |
Histology | |||
   differentiated | 14.5 | 9.1 - 18.2 | 0.357 |
   undifferentiated | 14.6 | 11.0 - 18.2 | |
No. of organs involved | |||
   1 | 12.8 | 10.1 - 15.4 | 0.414 |
   ≧ 2 | 16.9 | 14.4 - 19.3 | |
Liver metastasis | |||
   No | 16.0 | 12.7 - 19.3 | 0.237 |
   Yes | 10.4 | 3.5 - 17.3 | |
Peritoneum metastasis | |||
   No | 15.1 | 9.5 - 20.7 | 0.54 |
   Yes | 14.6 | 11.1 - 18.1 | |
Tumor response | |||
   No (SD or PD) | 8.6 | 6.0 - 11.2 | <0.001 |
   Yes (PR) | 18.2 | 12.7 - 23.7 | |
Second-line chemotherapy | |||
   No | 8.6 | 4.2 - 13.0 | 0.024 |
   Yes | 16.3 | 15.0 - 17.5 |